← Leaderboards
Jordan Green
Johns Hopkins University
$12,034,081
Attributed
$15,515,883
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,271,149 · 14
By mechanism
R01$11,178,635 · 6
P41$4,917,292 · 3
R21$1,733,097 · 4
R56$442,125 · 1
Top collaborators
- Alfredo Quinones-Hinojosa8 shared
- Peter A Campochiaro6 shared
- Hai-Quan Mao3 shared
- Joshua Charles Doloff2 shared
- Aleksander S. Popel2 shared
- Jonathan P Schneck2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Peter A Campochiaro$21,020,539
- James R. Eshleman$3,087,425
- Hai-Quan Mao$12,355,305
- Mark Gregory Luciano$10,508,934
- Drew M. Pardoll$27,059,898
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsNanoparticleSafetyIn VitroEngineeringTechnologyGene DeliveryPropertyFormulationTransfectionDesignMouse ModelTumorSpecificityBiocompatible MaterialsPolymersProteinsBiodegradable PolymerCell TypeParticleMediatingAffectNovel Therapeutics
Grant awards (49)
The Johns Hopkins Translational ImmunoEngineering (JH-TIE)$1,149,953
P41 · FY2025 · EB
Kinetic Assembly of Polymer-mRNA Nanoparticles Targets Circulating Monocytes to Enhance Cancer Immunotherapy$572,485
R01 · FY2025 · CA
TR&D Project 2$303,154
P41 · FY2025 · EB · contact PI
The Johns Hopkins Translational ImmunoEngineering (JH-TIE)$1,605,313
P41 · FY2024 · EB
Kinetic Assembly of Polymer-mRNA Nanoparticles Targets Circulating Monocytes to Enhance Cancer Immunotherapy$538,330
R01 · FY2024 · CA
TR&D Project 2$284,285
P41 · FY2024 · EB · contact PI
Tolerance-Inducing mRNA Nanoparticles to Treat Type 1 Diabetes$196,500
R56 · FY2024 · DK · contact PI
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists$598,945
R01 · FY2023 · EY
Kinetic Assembly of Polymer-mRNA Nanoparticles Targets Circulating Monocytes to Enhance Cancer Immunotherapy$560,955
R01 · FY2023 · CA
Gene Delivery Nanoparticles to Treat Glioblastoma$357,624
R01 · FY2023 · CA · contact PI
TR&D2: Nanoimmunomaterials for Immune Engineering$315,202
P41 · FY2023 · EB · contact PI
Tolerance-Inducing mRNA Nanoparticles to Treat Type 1 Diabetes$245,625
R56 · FY2023 · DK · contact PI
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists$580,975
R01 · FY2022 · EY
Gene Delivery Nanoparticles to Treat Glioblastoma$357,624
R01 · FY2022 · CA · contact PI
TR&D2: Nanoimmunomaterials for Immune Engineering$315,202
P41 · FY2022 · EB · contact PI
A Non-Viral Genetic Vaccine for Prevention and Treatment of Multiple Sclerosis$245,625
R21 · FY2022 · AI · contact PI
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists$580,975
R01 · FY2021 · EY
Gene Delivery Nanoparticles to Treat Glioblastoma$364,921
R01 · FY2021 · CA · contact PI
TR&D2: Nanoimmunomaterials for Immune Engineering$310,503
P41 · FY2021 · EB · contact PI
A Non-Viral Genetic Vaccine for Prevention and Treatment of Multiple Sclerosis$204,688
R21 · FY2021 · AI · contact PI
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists$598,945
R01 · FY2020 · EY
Gene Delivery Nanoparticles to Treat Glioblastoma$364,921
R01 · FY2020 · CA · contact PI
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)$363,722
R01 · FY2020 · CA
TR&D2: Nanoimmunomaterials for Immune Engineering$316,840
P41 · FY2020 · EB · contact PI
Gene Delivery Nanoparticles to Treat Glioblastoma$422,099
R01 · FY2019 · CA · contact PI
Cancer-specific nanoparticle-mediated gene therapy to treat hepatocellular carcinoma$364,500
R01 · FY2019 · EB · contact PI
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)$352,810
R01 · FY2019 · CA
TR&D2: Nanoimmunomaterials for Immune Engineering$316,840
P41 · FY2019 · EB · contact PI
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)$9,910
R01 · FY2019 · CA
Cancer-specific nanoparticle-mediated gene therapy to treat hepatocellular carcinoma$364,500
R01 · FY2018 · EB · contact PI
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)$363,623
R01 · FY2018 · CA
Administrative Supplement: Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer$55,777
R01 · FY2018 · CA
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)$364,553
R01 · FY2017 · CA
Cancer-specific nanoparticle-mediated gene therapy to treat hepatocellular carcinoma$364,500
R01 · FY2017 · EB · contact PI
Gene Delivery Nanoparticles to Treat Glioblastoma$364,500
R01 · FY2017 · EB · contact PI
Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases$204,401
R21 · FY2017 · EY · contact PI
Nanoparticle modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer$10,280
R01 · FY2017 · CA · contact PI
Gene Delivery Nanoparticles to Treat Glioblastoma$465,549
R01 · FY2016 · EB · contact PI
Nanoparticle modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer$370,575
R01 · FY2016 · CA · contact PI
Cancer-specific nanoparticle-mediated gene therapy to treat hepatocellular carcinoma$364,500
R01 · FY2016 · EB · contact PI
Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases$244,563
R21 · FY2016 · EY · contact PI
Gene Delivery Nanoparticles to Treat Glioblastoma$25,262
R01 · FY2016 · EB · contact PI
Gene Delivery Nanoparticles to Treat Glioblastoma$357,210
R01 · FY2015 · EB · contact PI
Gene Delivery Nanoparticles to Treat Glioblastoma$353,565
R01 · FY2014 · EB · contact PI
Biodegradable serpin-peptide-carrying nano- and microparticles for wet AMD$198,450
R21 · FY2014 · EY · contact PI
Gene Delivery Nanoparticles to Treat Glioblastoma$364,500
R01 · FY2013 · EB · contact PI
Biodegradable serpin-peptide-carrying nano- and microparticles for wet AMD$243,000
R21 · FY2013 · EY · contact PI
Nanoparticle-mediated peptide delivery for breast cancer$178,350
R21 · FY2012 · CA · contact PI
Nanoparticle-mediated peptide delivery for breast cancer$214,020
R21 · FY2011 · CA · contact PI